Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
Trial details
- Registry ID
- NCT06470451
- Drugs studied
- Hypericin
TrialRedline tracks 5 clinical trials sponsored by Soligenix: 1 Phase 3, 4 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCLNCT06470451 | Hypericin | Terminated | 2026-05-22Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Topical SGX302 for Mild-to-Moderate PsoriasisNCT05442190 | Hypericin | Completed | 2025-10-22Actual |
| Dusquetide for the Treatment of Behcet's DiseaseNCT06386744 | Dusquetide | Completed | 2025-05-23Actual |
| HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCLNCT06149247 | Hypericin, Mechlorethamine Topical Gel | Completed | 2024-05-31Actual |
| PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell LymphomaNCT05380635 | Hypericin | Completed | 2022-08-16Actual |
Names as written in the registry records.
NCT05442190 · Soligenix
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Number of patients that achieve a 0 or 1 score using the 5-point Investigator's Global Assessment scale Description: The percentage of patients in each treatment group that achieve a 0 or 1 score (Clear or Almost Clear) evaluation using the 5-point Investigator's Global Assessment (IGA) scale. The 5-point IGA scale: * Score 0: Clear - No signs of psoriasis; post-inflammatory hyperpigmentation may be present * Score 1: Almost Clear - No thickening; normal to pink coloration; no to minimal focal scaling * Score 2: Mild - Just detectable to mild thickening; pink to light red coloration; predominantly fine scaling * Score 3: Moderate - Clear distinguishable to moderate thickening; dull to bright red; moderate scaling * Score 4: Severe - Severe thickening with hard edges; bright to deep red coloration; severe/coarse scaling covering almost all lesions Time frame: 18 weeks. After: Measure: Number of Patients That Achieve a 0 or 1 Score Using the 5-point Investigator's Global Assessment Scale Description: The percentage of patients in each treatment group that achieve a 0 or 1 score (Clear or Almost Clear) evaluation using the 5-point Investigator's Global Assessment (IGA) scale. The 5-point IGA scale: * Score 0: Clear - No signs of psoriasis; post-inflammatory hyperpigmentation may be present * Score 1: Almost Clear - No thickening; normal to pink coloration; no to minimal focal scaling * Score 2: Mild - Just detectable to mild thickening; pink to light red coloration; predominantly fine scaling * Score 3: Moderate - Clear distinguishable to moderate thickening; dull to bright red; moderate scaling * Score 4: Severe - Severe thickening with hard edges; bright to deep red coloration; severe/coarse scaling covering almost all lesions Time frame: 18 weeks.
NCT06470451 · Soligenix
Before: Estimated. After: Actual.
Before: 80 participants (planned). After: 70 participants (actual).
Before: Estimated. After: Actual.
Before: Jul 2026. After: 22 May 2026.
Before: Recruiting. After: Terminated.
NCT05442190 · Soligenix
Before: Estimated. After: Actual.
Before: 47 participants (planned). After: 15 participants (actual).
Before: Estimated. After: Actual.
Before: Oct 2025. After: 22 Oct 2025.
Before: Recruiting. After: Completed.